The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2
Copyright © 2022 Li, Gao, Liu, Liu, Wu, Dai, Han and Li..
The receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, which is a prerequisite for the virus to enter the cell. C-reactive protein (CRP) is an important marker of inflammation and is a putative soluble pattern recognition receptor. Clinical elevation of CRP levels in patients with COVID-19 is one of the characteristics of the disease; however, whether CRP is involved in COVID-19 pathogenesis is unknown. Here, we report that monomeric CRP (mCRP) can bind to the SARS-CoV-2 spike RBD and competitively inhibit its binding to ACE2. Furthermore, truncated mutant peptide competition assays and surface plasmon resonance binding experiments showed that the cholesterol-binding sequence (CBS, amino acids 35-47) in mCRP was critical for mediating the binding of mCRP to spike RBD. In a cell model of spike RBD and ACE2 interaction, the CBS motif effectively reduced the binding of spike RBD to ACE2 overexpressed on the cell surface. Thus, this study highlights the pattern recognition function of mCRP in innate immunity and provides a preliminary theoretical basis for the development of the CBS motif in mCRP into a functional peptide with both diagnostic significance and potential therapeutic capabilities.
| Errataetall: |
ErratumIn: Front Immunol. 2022 Sep 12;13:1011789. - PMID 36177030 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 15., Seite 918731 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Hai-Yun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.07.2022 Date Revised 30.09.2022 published: Electronic-eCollection ErratumIn: Front Immunol. 2022 Sep 12;13:1011789. - PMID 36177030 Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.918731 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343945711 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343945711 | ||
| 003 | DE-627 | ||
| 005 | 20231226205027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.918731 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343945711 | ||
| 035 | |a (NLM)35874670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Hai-Yun |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2022 | ||
| 500 | |a Date Revised 30.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ErratumIn: Front Immunol. 2022 Sep 12;13:1011789. - PMID 36177030 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Li, Gao, Liu, Liu, Wu, Dai, Han and Li. | ||
| 520 | |a The receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, which is a prerequisite for the virus to enter the cell. C-reactive protein (CRP) is an important marker of inflammation and is a putative soluble pattern recognition receptor. Clinical elevation of CRP levels in patients with COVID-19 is one of the characteristics of the disease; however, whether CRP is involved in COVID-19 pathogenesis is unknown. Here, we report that monomeric CRP (mCRP) can bind to the SARS-CoV-2 spike RBD and competitively inhibit its binding to ACE2. Furthermore, truncated mutant peptide competition assays and surface plasmon resonance binding experiments showed that the cholesterol-binding sequence (CBS, amino acids 35-47) in mCRP was critical for mediating the binding of mCRP to spike RBD. In a cell model of spike RBD and ACE2 interaction, the CBS motif effectively reduced the binding of spike RBD to ACE2 overexpressed on the cell surface. Thus, this study highlights the pattern recognition function of mCRP in innate immunity and provides a preliminary theoretical basis for the development of the CBS motif in mCRP into a functional peptide with both diagnostic significance and potential therapeutic capabilities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cholesterol-binding sequence | |
| 650 | 4 | |a monomeric C-reactive protein | |
| 650 | 4 | |a pattern recognition receptor | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Gao, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Cheng-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiao-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Nini |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiu-Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 15., Seite 918731 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:15 |g pages:918731 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.918731 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 15 |h 918731 | ||